Curated CRC research — accessible, accurate, actionable

The CRC Digest

Sunday, August 09, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  13-Year NordICC Data Show Colonoscopy Reduces CRC Incidence but Not Mortality

  Long-term follow-up from the NordICC trial comparing colonoscopy to no screening found a reduction in colorectal cancer incidence but no statistically significant mortality benefit at 13 years. (Gastroenterology)

• ◇ RESEARCH

  ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection

  A review of circulating tumor DNA in GI cancers found that while postoperative ctDNA positivity identifies high-risk patients, recent trials show mixed results: DYNAMIC-III showed escalation in ctDNA-positive stage III disease did not improve outcomes. (EClinicalMedicine)

• ▸ TREATMENT

  Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC

  A study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)

• ♥ LIVING WITH CRC

  Early Palliative Care Contact Linked to Reduced End-of-Life Healthcare Use

  A nationwide Finnish study found that early specialist palliative care involvement (more than 30 days before death) was associated with lower healthcare utilization at end of life in patients with colorectal and intestinal cancers. (Cancer Control)

Research continues to refine how we screen, treat, and support patients across the CRC journey.